TherapeuticsMD (NASDAQ:TXMD) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research report report published on Sunday morning. The firm issued a hold rating on the stock.

TherapeuticsMD Stock Performance

NASDAQ TXMD opened at $1.54 on Friday. The stock’s 50 day moving average price is $1.66 and its two-hundred day moving average price is $1.80. TherapeuticsMD has a 52 week low of $1.43 and a 52 week high of $3.07.

TherapeuticsMD (NASDAQ:TXMD) last released its earnings results on Monday, August 12th. The company reported ($0.09) EPS for the quarter. The business had revenue of $0.23 million during the quarter.

Institutional Investors Weigh In On TherapeuticsMD

A hedge fund recently raised its stake in TherapeuticsMD stock. Clearline Capital LP lifted its stake in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 636,622 shares of the company’s stock after purchasing an additional 101,282 shares during the period. Clearline Capital LP owned 5.52% of TherapeuticsMD worth $1,025,000 at the end of the most recent quarter. 30.74% of the stock is currently owned by institutional investors.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.